Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for celg
121.16
+2.50 (2.11%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 118.81 - 121.19
52 week 94.39 - 127.00
Open 119.13
Vol / Avg. 4.86M/4.42M
Mkt cap 96.24B
P/E 48.73
Div/yield     -
EPS 2.49
Shares 777.97M
Beta 1.74
Inst. own 80%
Jan 26, 2017
Q4 2016 Celgene Corp Earnings Release (Estimated)
Jan 9, 2017
Celgene Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 9, 2017
Celgene Corp at JPMorgan Healthcare Conference
Dec 16, 2016
Evotec AG And Celgene Enter Into Drug Discovery Collaboration For Neurodegenerative Diseases Corporate Call
Dec 5, 2016
Acceleron Pharma Inc Conference Call to Review Data Presented at American Society of Hematology Annual Meeting - Webcast
Dec 4, 2016
Celgene Corp Analyst and Investor Event at American Society of Hematology (ASH) - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 14.39% 17.80%
Operating margin 21.08% 25.02%
EBITD margin - 33.76%
Return on average assets 6.27% 7.26%
Return on average equity 28.09% 31.94%
Employees 7,132 -
CDP Score - 97 C

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jacqualyn A. Fouse Ph.D. President, Chief Operating Officer, Director
Age: 55
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Chairman - Celgene Research
Age: 62
Bio & Compensation  - Reuters
Scott A. Smith Global President - Inflammation & Immunology
Age: 54
Bio & Compensation  - Reuters
Rupert Vessey President - Research and Early Development
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 57
Bio & Compensation  - Reuters